The bleomycins (BLMs) are a family of glycopeptide anticancer antibiotics isolated from a fermentation broth of Streptomyces verticillus.1Streptomyces verticillus var. pingyangensis n. var., isolated from a soil sample collected in Pingyang, Zhejiang Province, China, produces a complex of antitumor antibiotics belonging to the BLM family.2 We investigated it and discovered NC1101, a new analog of BLM with a tetrahydropyrimidine ring in the terminal amine.
The strain was maintained on an agar slant consisting of glucose 1.0%, soluble amylum 1.0%, peptone 0.5%, agar 2.0% and NaCl 0.5%, pH 7.5, incubated for 7 days at 28 °C. Seed medium and producing medium shared the same components; that is, soluble amylum 2.5%, glucose 0.5%, soybean meal 3.5%, KH2PO4 0.1%, ZnSO4 0.05% and CuSO4 0.01%, pH 6.5. The slant was transferred to 250 ml Erlenmeyer flasks containing 50 ml of seed medium, and then they were incubated at 28 °C on a rotary shaker at 220 r.p.m. for 2 days. A total of 10 ml of the seed medium was transferred to a 500-ml Erlenmeyer flask containing 100 ml of the producing medium. The fermentation was carried out at 29 °C for 7∼8 days on a rotary shaker at 220 r.p.m. Paper-disk agar diffusion assay using Bacillus subtilis was adopted to measure the antibiotic activity.
Fermentation broth (20 l) was adjusted to pH 2∼3 with oxalic acid and filtered. The filtrate was charged on a 122 resins (H+ form, 2 l) column, and then sequently eluted with distilled water (3 l) and 0.3 M HCl (6 l). The active eluents were pooled and adjusted to pH 7, then 0.2% (w/v) CuSO4 was added. The solution was desalted on a resin column. The active fractions were eluted with water-acetone (90:10, v/v) mixture containing 0.01 M HCl, then combined and evaporated in vacuo. The resulting solution was chromatographed on a column of CM-Sephadex C-25 (NH4+ form, 300 ml), and eluted with a stepwise gradient of NH4Cl solution (0.1–0.6 M). The first blue fraction was desalted, and subjected to a CM-Sephadex C-25 column (NH4+ form, 100 ml) again, then eluted with 0.05 M NH4Cl. As a result, copper-chelated NC1101 was purified. The solution was desalted, concentrated and lyophilized. The resulting blue powder (126 mg) was treated with dithizone to give copper-free compound NC1101 (98 mg).
Copper-free NC1101: white powder; UV , nm: 233∼235(sh.) (24 460), 293∼295 (16 423); ESI-MS, m z−1 1507.27 [M+H]+, 754.46 [M+2 H]2+, 503.67 [M+3 H]3+. UV spectra were collected by SHIMADZU UV-2550 (SHIMADZU, Tokyo, Japan), mass spectra were obtained from Thermo LTQ XL MS instrument (ThermoFisher Scientific, San Jose, CA, USA).
NC1101 showed a typical UV spectrum similar to that of BLM. Ninhydrin reaction of NC1101 was non-typical. Sakaguchi reaction was negative, indicated the absence of guanidine in the structure of NC1101, which could not be a compound of BLM B family. The molecular mass of copper chelated NC1101 was 1569.66 on the basis of ESI-MS data, which gave a molecular ion at m z−1 784.83 [M+Cu]2+ and a quasi-molecular ion at m z−1 523.67 [M+Cu+H]3+. The fragment ions at m z−1 682.42 [M+Cu –Carbamylmannosyl+H]2+ and 602.25 [M+Cu-Carbamylmannosyl-Gulosyl+H]2+ revealed that the typical glycannic part of BLMs was contained. In the 13C NMR spectrum, the two anomeric carbon signals at δC 100.6 (G-1) and δC 100.7 (M-1) pointed to the same conclusion.
We assigned the 13C NMR signals by comparison with 13C NMR spectrum data of NC0604 in the previous paper,4 and by analysis of 1H-1H COSY, HMQC, HMBC, DEPT spectra of NC1101. NMR spectra were recorded in D2O with Varian VNS-600 spectrometer (Varian, San Francisco, CA, USA). The signals of the carbons constituting the kernel structure of NC1101 were consistent with those of NC0604 and the difference between NC1101 and NC0604 was in the terminal amine. The numbering of the parts in the NC1101 molecule follows the convention used in the previous paper5 as shown in Figure 1. The 13C NMR spectral data of the kernel structure of NC1101 were tabulated in Table 1 in comparison with those of NC0604.4
The DEPT spectrum showed 1 methane and 10 methylenes in the terminal amine of NC1101. According to 1H-1H COSY and HMQC spectra, the connections of these methylenes were identified. The sequence from δH 3.56 (R-a) to δH 3.17 (R-c) through δH 2.07 (R-b), from δH 3.47 (R-h) to δH 3.37 (R-j) through δH 2.06 (R-i), and the correlated signals of δH 3.13 (R-d) and δH 1.74 (R-e), δH 1.74 (R-e) and δH 1.79 (R-f), δH 1.79 (R-f) and δH 3.51 (R-g) indicated the presence of three aliphatic chains that were confirmed by the HMBC spectrum.
In the HMBC spectrum, the crossing peaks between δH 3.17 (R-c) and δC 50.0 (R-d), δH 3.13 (R-d) and δC 48.1 (R-c), δH 3.51 (R-g) and δC 46.2 (R-h), δH 3.47 (R-h) and δC 57.0 (R-g) demonstrated the sequence of the three aliphatic chains (Figure 2). The methane proton signal at δH 7.95 (R-CH) showed coupling to δC 57.0 (R-g), δC 46.2 (R-h) and δC 39.9 (R-j), the double-bond carbon signal at δC 155.2 (R-CH) showed coupling to the protons at δH 3.51 (R-g), δH 3.47 (R-h) and δH 3.37 (R-j). The nitrogen atom attachments to R-g, R-h and R-j, which were revealed by the 13C chemical shift of these carbons, demonstrated the presence of a nitrogen-containing heterocyclic ring in the terminal amine. Furthermore, the linkage of the terminal amine and the bleomycinamide was established with the correlated signal of δH 3.56 (R-a) and δC 166.4 (VI-CO). Eventually, the structure of the terminal amine was determined, and the 1H-1H COSY and selective HMBC correlations were indicated in Figure 2. The assignments for carbon signals of the terminal amine of NC1101 were shown in Table 1.
References
Umezawa, H., Maeda, K., Takeuchi, T. & Okami, Y. New antibiotics, bleomycin A and B. J. Antibiot. 19, 200–209 (1966).
Zhao, Y. Y., Xie, M. Y. & Wang, G. L. Studies on Zhengguangmycins. Taxonomy of Streptomyces verticillus var. pingyangensis n.var. Acta. Microbiologica. Sinica. 19, 361 (1979).
Raisfeld, I. H. Role of terminal substituents in the pulmonary toxicity of bleomycins. Toxicol. Appl. Pharmacol. 57, 355–366 (1981).
Chen, C. X. et al Isolation and characterization of antibiotic NC0604, a new analogue of bleomycin. J. Antibiot. 61, 747–751 (2008).
Naganawa, H., Muraoka, Y., Takita, T. & Umezawa, H. Chemistry of bleomycin. XVIII. Carbon-13 NMR studies. J. Antibiot. 30, 388–396 (1977).
Tim Mosmann Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).
Acknowledgements
This study was supported by the Key New Drug Creation and Manufacturing Programn (Grant No. 2012ZX09301002-001) funded by the Ministry of Science and Technology of the People’s Republic of China.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ren, H., Lu, M., Xie, YY. et al. NC1101, a novel tetrahydropyrimidine-containing bleomycin analog from Streptomyces verticillus var. pingyangensis n. var.. J Antibiot 65, 327–329 (2012). https://doi.org/10.1038/ja.2012.23
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ja.2012.23
Keywords
This article is cited by
-
Exploring novel herbicidin analogues by transcriptional regulator overexpression and MS/MS molecular networking
Microbial Cell Factories (2019)
-
The discovery and development of microbial bleomycin analogues
Applied Microbiology and Biotechnology (2018)